Collegium (COLL) Schedule 13G: Group reports shared 4.7% stakes

Collegium Pharmaceutical, Inc. group investors reported shared beneficial ownership positions in Common Stock after briefly exceeding 5% on 05/07/2026.

Rhea-AI Filing Summary

Collegium Pharmaceutical, Inc. group investors reported shared beneficial ownership positions in Common Stock after briefly exceeding 5% on 05/07/2026. The filing lists Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander as filing together under a Joint Filing Agreement.

The cover entries show shared voting power and shared dispositive power of 1,515,406 and 1,519,500 common shares for specific reporting entities, each representing approximately 4.7% of the class in the disclosed rows. The filing states the reporting persons ceased to be beneficial owners of more than 5% by the filing date.

Insights

Corporate Governance Analyst

Group investors filed a joint Schedule 13G reporting shared positions just after a >5% threshold event.

The schedule lists commonholders acting together through entities under Millennium control and identifies specific shared voting and dispositive power figures: 1,515,406 and 1,519,500 shares in the excerpt. The filing includes a Joint Filing Agreement dated May 11, 2026.

Relevant dependencies include the group classification and timing: the filing notes the persons "ceased to be beneficial owners of more than 5%" after acquiring that status on 05/07/2026. Subsequent disclosures or exhibits may clarify exact holdings across all group members.

Regulatory Compliance Specialist

The submission follows Schedule 13G group-reporting conventions and attaches an exhibit identifying members.

The excerpt shows shared control of specific share counts and flags that holdings are held by entities subject to Millennium Management's voting/investment discretion. The filing includes signatures and an Exhibit I joint filing agreement dated May 11, 2026.

Cash‑flow treatment and transactional detail are not provided in the excerpt; the disclosure focuses on ownership classification and group attribution.

Key Figures

Shared voting power (Integrated Core row): 1,515,406 shares Shared voting power (Millennium rows): 1,519,500 shares Percent of class shown: 4.7% +2 more

5 metrics

Shared voting power (Integrated Core row) 1,515,406 shares cover entry showing shared voting/dispositive power

Shared voting power (Millennium rows) 1,519,500 shares cover entries showing shared voting/dispositive power

Percent of class shown 4.7% percent of class reported on cover rows

Threshold date 05/07/2026 date when beneficial ownership exceeded 5%

Joint Filing Agreement date 05/11/2026 Exhibit I joint filing agreement date

Key Terms

Schedule 13G, Shared dispositive power, Joint Filing Agreement, Beneficial ownership

4 terms

Schedule 13G regulatory

"Item 1. Name of issuer: Collegium Pharmaceutical, Inc.; form type: SCHEDULE 13G"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Shared dispositive power regulatory

"Shared Dispositive Power 1,515,406.00 / 1,519,500.00"

Joint Filing Agreement legal

"Exhibit I: Joint Filing Agreement, dated as of May 11, 2026"

Beneficial ownership regulatory

"ceased to be beneficial owners of more than 5% of the outstanding Common Stock"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Collegium (COLL) Schedule 13G filed May 2026 disclose?

The filing discloses joint reporting by Integrated Core Strategies, Millennium entities, and Israel A. Englander. It lists shared voting and dispositive power for specific rows of 1,515,406 and 1,519,500 shares and a Joint Filing Agreement dated May 11, 2026.

Who are the reporting persons in the COLL Schedule 13G?

The reporting persons are Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, all listed with addresses at 399 Park Avenue, New York.

How many shares and what percent are shown for each reporting row?

The excerpt shows shared power rows of 1,515,406 and 1,519,500 shares in the cover entries, each noted as approximately 4.7% of the class in those lines.

Did the filers remain above 5% ownership?

The filing states the reporting persons "ceased to be beneficial owners of more than 5% of the outstanding Common Stock by the date of this filing" after acquiring over 5% on May 7, 2026.

Is there a joint filing agreement in the COLL submission?

Yes. The filing references and attaches an Exhibit I: Joint Filing Agreement dated May 11, 2026 among the named reporting persons.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/12/2026 - 05:55 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Collegium Pharmaceutical, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

19459J104

(CUSIP Number)

05/07/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 19459J104

1

Names of Reporting Persons

Integrated Core Strategies (US) LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,515,406.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,515,406.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,515,406.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.7 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 19459J104

1

Names of Reporting Persons

Millennium Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,519,500.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,519,500.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,519,500.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.7 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 19459J104

1

Names of Reporting Persons

Millennium Group Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,519,500.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,519,500.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,519,500.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.7 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 19459J104

1

Names of Reporting Persons

Israel A. Englander

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,519,500.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,519,500.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,519,500.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.7 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Collegium Pharmaceutical, Inc.
(b)	Address of issuer's principal executive offices: 100 Technology Center Drive, Stoughton, Massachusetts 02072
Item 2.
(a)	Name of person filing: Integrated Core Strategies (US) LLC Millennium Management LLC Millennium Group Management LLC Israel A. Englander
(b)	Address or principal business office or, if none, residence: Integrated Core Strategies (US) LLC c/o Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
(c)	Citizenship: Integrated Core Strategies (US) LLC - Delaware Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP Number(s): 19459J104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to Item 9 on each cover page. After acquiring beneficial ownership of more than 5% of the outstanding Common Stock on May 7, 2026, the reporting persons ceased to be beneficial owners of more than 5% of the outstanding Common Stock by the date of this filing.
(b)	Percent of class: See response to Item 11 on each cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to Item 5 on each cover page.
	(ii) Shared power to vote or to direct the vote: See response to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. See Exhibit I
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Integrated Core Strategies (US) LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	05/11/2026

Millennium Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	05/11/2026

Millennium Group Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	05/11/2026

Israel A. Englander

Signature:	/s/ Israel A. Englander
Name/Title:	Israel A. Englander
Date:	05/11/2026

Comments accompanying signature: ** INTEGRATED CORE STRATEGIES (US) LLC By: Integrated Holding Group LP, its Managing Member By: Millennium Management LLC, its General Partner

Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of May 11, 2026, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.